DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ENSTILAR
» See Plans and Pricing
All Clinical Trials for Enstilar
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02881346 | Efficacy and Tolerability of Enstilar® in Daily Practice | Recruiting | LEO Pharma | N/A | 2016-10-01 | This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany, |
| NCT02935582 | PSOREAL - Managing PSOriasis in the REAL World | Not yet recruiting | LEO Pharma | N/A | 2016-10-01 | Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate). |
| NCT03441789 | Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis | Recruiting | Leon Kircik, M.D. | Phase 4 | 2017-09-18 | This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam. |
| NCT03506477 | Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color | Recruiting | Icahn School of Medicine at Mount Sinai | Phase 4 | 2018-05-21 | This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life. |
| NCT03587194 | Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis | Recruiting | Celgene Corporation | Phase 4 | 2018-07-23 | Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Enstilar
Condition Name
Clinical Trial Locations for Enstilar
Trials by Country
Clinical Trial Progress for Enstilar
Clinical Trial Phase
Clinical Trial Sponsors for Enstilar
Sponsor Name
